Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,439,945
  • Shares Outstanding, K 16,078
  • Annual Sales, $ 120,280 K
  • Annual Income, $ 629,300 K
  • 60-Month Beta 1.45
  • Price/Sales 12.03
  • Price/Cash Flow 15.04
  • Price/Book 2.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.56
  • Number of Estimates 1
  • High Estimate 0.56
  • Low Estimate 0.56
  • Prior Year 0.15
  • Growth Rate Est. (year over year) +273.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.44 +6.56%
on 09/21/20
111.70 -16.58%
on 08/24/20
-18.80 (-16.79%)
since 08/21/20
3-Month
87.44 +6.56%
on 09/21/20
127.80 -27.09%
on 07/30/20
-22.34 (-19.34%)
since 06/23/20
52-Week
57.24 +62.79%
on 03/17/20
127.80 -27.09%
on 07/30/20
-11.78 (-11.22%)
since 09/23/19

Most Recent Stories

More News
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million

--Continued clinical progress of Captisol-enabled drugs affirms the value of the proprietary technology

LGND : 93.18 (+4.04%)
Ligand Pharmaceuticals Enters Oversold Territory

Ligand Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

LGND : 93.18 (+4.04%)
Ligand Expands OmniAb(R) Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb(R) technology platform. Ligand acquired xCella Biosciences,...

LGND : 93.18 (+4.04%)
LGND or ALKS: Which Is the Better Value Stock Right Now?

LGND vs. ALKS: Which Stock Is the Better Value Option?

LGND : 93.18 (+4.04%)
ALKS : 16.83 (-1.92%)
Ligand (LGND) Down 13.7% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LGND : 93.18 (+4.04%)
Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference.

LGND : 93.18 (+4.04%)
Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the "Purchaser"), is commencing a tender offer to purchase all outstanding...

PFNX : 12.71 (-1.17%)
LGND : 93.18 (+4.04%)
Ligand OmniAb(R) Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis

--Registration-enabling Phase 3 trial expected to initiate in the first half of 2021

LGND : 93.18 (+4.04%)
IMVT : 33.76 (-5.59%)
LGND vs. ILMN: Which Stock Is the Better Value Option?

LGND vs. ILMN: Which Stock Is the Better Value Option?

LGND : 93.18 (+4.04%)
ILMN : 273.00 (+1.67%)
Ligand Announces Amgen's KYPROLIS(R) Approved by FDA as Combination Regimen with DARZALEX(R) and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma

--Approval based on the CANDOR and EQUULEUS Studies

LGND : 93.18 (+4.04%)
AMGN : 242.59 (-1.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade LGND with:

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 102.10
1st Resistance Point 97.64
Last Price 93.18
1st Support Level 90.68
2nd Support Level 88.18

See More

52-Week High 127.80
Fibonacci 61.8% 100.85
Last Price 93.18
Fibonacci 50% 92.52
Fibonacci 38.2% 84.19
52-Week Low 57.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar